Demand for GLP-1 drugs is soaring. Thanks to recent breakthroughs, medicines in this category are expanding their addressable markets and treating conditions such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatohepatitis, and others, in addition to diabetes and weight management, which are perhaps their most important areas. Eli Lilly (NYSE: LLY) is a leader in…
Demand for GLP-1 drugs is soaring. Thanks to recent breakthroughs, medicines in this category are expanding their addressable markets and treating conditions such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatohepatitis, and others, in addition to diabetes and weight management, which are perhaps their most important areas.
Eli Lilly (NYSE: LLY) is a leader in this space, but several companies are looking to take its crown. One of them is Viking Therapeutics (NASDAQ: VKTX), a smaller biotech with promising GLP-1 candidates. Could Viking Therapeutics successfully challenge Eli Lilly? Let’s find out which of these two stocks is a better buy for investors looking to capitalize on this opportunity.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: The Motley Fool.
Eli Lilly is firing on all cylinders
Eli Lilly’s tirzepatide, which mimics the action of both the GLP-1 and GIP hormones, is approved for diabetes, weight loss, and OSA. It is by far the company’s most important growth driver right now and the best-selling medicine in this niche. In the second quarter, Eli Lilly’s revenue increased by 48% year over year to $23 billion. Sales of Mounjaro — the brand name for tirzepatide in the diabetes market — soared 91% year over year to $9.9 billion. Zepbound’s (tirzepatide’s brand in weight management) revenue was $4.9 billion, up 46% compared to the year-ago period.
Eli Lilly also markets Foundayo, an oral GLP-1 that is helping expand the market by attracting mostly new patients. It isn’t generating meaningful revenue yet, at least by Eli Lilly’s standards, but once it expands beyond weight loss and into diabetes, OSA, and other indications, it could start making substantial contributions to top-line growth.
Eli Lilly has a deep pipeline beyond these approved products. The most promising is retatrutide, a medicine that posted outstanding phase 3 clinical trial results in diabetes and weight loss. Eli Lilly plans to request approval for retatrutide in the first quarter of 2027. Eli Lilly looks likely to maintain its lead in this market for the foreseeable future, and it also has attractive approved products and pipeline candidates in other areas.
Viking Therapeutics has key catalysts ahead
Viking Therapeutics is a clinical-stage biotech. The company’s leading candidate, VK2735, looks promising. Just like tirzepatide, VK2735 is a dual GLP-1 and GIP agonist. A subcutaneous version of the medicine is undergoing phase 3 studies, while the drugmaker should start late-stage trials for an oral formulation by year-end. Subcutaneous VK2735 posted excellent results in phase 2 studies. It led to a mean weight loss of up to 14.7% in 13 weeks, with no plateau observed.
The usual caveats about comparing across clinical trials aside, tirzepatide posted an average weight loss of 20.2% in 72 weeks in a phase 3 study. Perhaps subcutaneous VK2735 can match — or even exceed — tirzepatide’s efficacy in the longer clinical trials in which it is being tested. The oral formulation of the medicine also showed highly encouraging phase 2 efficacy, although there were concerns about high rates of discontinuation due to side effects. Still, Viking Therapeutics could see its share soar on solid phase 3 data for both formulations.
Which is the better buy?
There is no contest between these two companies if we focus on fundamentals. Eli Lilly is a well-established pharmaceutical leader with a deep product portfolio that generates consistent revenue and earnings. Viking Therapeutics doesn’t have a single approved product, generates no revenue, is not profitable, and may not be for a while. However, Viking Therapeutics arguably has more upside potential.
If the company’s upcoming data readouts are robust enough and it can carve out a niche in the rapidly growing GLP-1 market, its shares will rise significantly from current levels — they could easily double (or more) in the next couple of years and continue delivering strong returns through the end of the decade.
But that significant upside potential also comes with a hefty dose of risk: Viking Therapeutics’ shares will fall off a cliff if VK2735 disappoints. So, which GLP-1 stock is better? I’d opt for Eli Lilly. The larger drugmaker has a deep portfolio and pipeline in this field and can beat the market as it continues to capitalize on soaring GLP-1 demand, with limited downside risk compared to Viking Therapeutics.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $399,724!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!*
That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.
See the 10 stocks »
*Stock Advisor returns as of August 8, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Viking Therapeutics. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? was originally published by The Motley Fool
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
